Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): a review.

Ovarian hyperstimulation syndrome (OHSS) is a rare iatrogenic complication of ovarian stimulation occurring during the luteal phase or during early pregnancy. Fortunately, the reported prevalence of the severe form of OHSS is small, ranging from 0.5 to 5%. Nevertheless, as this is an iatrogenic complication of a non-vital treatment with a potentially fatal outcome, the syndrome remains a serious problem for specialists dealing with infertility. The aim of this literature review was to determine whether it is possible to identify patients at risk, and which preventive method should be applied when an exaggerated ovarian response occurs. Data pertaining to the epidemiology and prevention of OHSS in women were searched using Medline, Current Contents and PubMed, and are summarized. Preventive strategies attempt either to limit the dose or concentration of hCG or to find a way to induce luteolysis without inducing a detrimental effect on endometrial and oocyte quality. The following particular preventive strategies were reviewed: cancelling the cycle; coasting; early unilateral ovarian follicular aspiration (EUFA); modifying the methods of ovulation triggering; administration of glucocorticoids, macromolecules and progesterone; cryopreservation of all embryos; and electrocautery or laser vaporization of one or both ovaries.

[1]  N. Dean,et al.  Comparison of intravenous albumin and transfer of fresh embryos with cryopreservation of all embryos for subsequent transfer in prevention of ovarian hyperstimulation syndrome. , 1996, Fertility and sterility.

[2]  S. Coskun,et al.  Pregnancy after transfer of embryos which were generated from in-vitro matured oocytes. , 1997, Human reproduction.

[3]  S. Stone,et al.  The use of intravenous albumin in patients at high risk for severe ovarian hyperstimulation syndrome. , 1993, Human reproduction.

[4]  J. Gerris,et al.  Triggering of ovulation using a gonadotrophin-releasing hormone agonist does not prevent ovarian hyperstimulation syndrome. , 1993, Human reproduction.

[5]  M. Sauer,et al.  Defining the incidence of serious complications experienced by oocyte donors: a review of 1000 cases. , 2001, American journal of obstetrics and gynecology.

[6]  R. Casper,et al.  Adhesion Formation After Laparoscopic Ovarian Cautery for Polycystic Ovarian Syndrome: Lack of Correlation With Pregnancy Rate , 1994 .

[7]  A. Balen,et al.  Diagnosis, prevention and management of ovarian hyperstimulation syndrome , 1995, British journal of obstetrics and gynaecology.

[8]  Crooke Ac.  Induction of ovulation with gonadotrophins. , 1970 .

[9]  B. Lieberman,et al.  Is continuation of a gonadotrophin-releasing hormone agonist (GnRHa) necessary for women at risk of developing the ovarian hyperstimulation syndrome? , 1992, Human reproduction.

[10]  T. Tulandi,et al.  Ovarian hyperstimulation syndrome following ovulation induction with human menopausal gonadotropin. , 1984, International journal of fertility.

[11]  F. Ellis,et al.  Ovulation stimulation. Problems of prediction of response to gonadotrophins. , 1970, Lancet.

[12]  L. Wildt,et al.  Endocrinology: von Willebrand factor: an endothelial marker to monitor in-vitro fertilization patients with ovarian hyperstimulation syndrome , 1993 .

[13]  R. Casper.  Does triggering ovulation with gonadotrophin-releasing hormone analogue prevent severe ovarian hyperstimulation syndrome? , 1996 .

[14]  C. R. Thompson,et al.  Pergonal (Menotropins): A Summary of Clinical Experience in the Induction of Ovulation and Pregnancy , 1970 .

[15]  Z. Ben-Rafael,et al.  Severe ovarian hyperstimulation syndrome despite low plasma oestrogen concentrations in a hypogonadotrophic, hypogonadal patient. , 1996, Human reproduction.

[16]  Z. Shoham,et al.  Ovarian hyperstimulation: effects of GnRH analogues. Triggering the final stage of ovulation using gonadotrophin-releasing hormone analogues: effective dose, prevention of ovarian hyperstimulation syndrome and the luteal phase. , 1996, Human reproduction.

[17]  J. Honour,et al.  Laparoscopic ovarian diathermy in the management of anovulatory infertility in women with polycystic ovaries: endocrine changes and clinical outcome. , 1990, Fertility and sterility.

[18]  M. Ferin,et al.  Mechanisms regulating the menstrual cycle in women. , 1970, Recent progress in hormone research.

[19]  M. Brunner,et al.  Prediction of ovarian hyperstimulation syndrome by ultrasound volumetric assessment [corrected] of baseline ovarian volume prior to stimulation. , 1996, Human reproduction.

[20]  A. Golan,et al.  Ovarian hyperstimulation syndrome following D-Trp-6 luteinizing hormone-releasing hormone microcapsules and menotropin for in vitro fertilization. , 1988, Fertility and sterility.

[21]  S. Araki,et al.  Does i.v. albumin prevent ovarian hyperstimulation syndrome? , 1999, Human reproduction.

[22]  A. Golan,et al.  Pregnancy rate and ovarian hyperstimulation after luteal human chorionic gonadotropin in in vitro fertilization stimulated with gonadotropin-releasing hormone analog and menotropins. , 1990, Fertility and sterility.

[23]  T. Tomaževič,et al.  Preventing severe ovarian hyperstimulation syndrome in an in vitro fertilization/embryo transfer program. Use of follicular aspiration after human chorionic gonadotropin administration. , 1995, The Journal of reproductive medicine.

[24]  R. Frydman,et al.  Une alternative à la réduction embryonnaire: la réduction folliculaire , 1984 .

[25]  A. Golan,et al.  Ovarian hyperstimulation syndrome: an update review. , 1989 .

[26]  P. De Grandi,et al.  A low-dose stimulation protocol using highly purified follicle-stimulating hormone can lead to high pregnancy rates in in vitro fertilization patients with polycystic ovaries who are at risk of a high ovarian response to gonadotropins. , 2001, Fertility and sterility.

[27]  W. Dodson,et al.  Ovarian hyperstimulation in polycystic ovary syndrome during therapy with leuprolide acetate. , 1989, Fertility and sterility.

[28]  P. Vandekerckhove,et al.  Ovulation induction with urinary follicle stimulating hormone versus human menopausal gonadotropin for clomiphene-resistant polycystic ovary syndrome. , 1996, The Cochrane database of systematic reviews.

[29]  D. Serr,et al.  Thromboembolic phenomena after ovarian stimulation with human gonadotrophins. , 1965, Lancet.

[30]  R. Casper,et al.  Gonadotropin-releasing hormone agonist versus human chorionic gonadotropin for triggering follicular maturation in in vitro fertilization. , 1992, Fertility and sterility.

[31]  Y. Englert,et al.  The ovarian hyperstimulation syndrome in in-vitro fertilization: a Belgian multicentric study. I. Clinical and biological features. , 1993, Human reproduction.

[32]  M. Brunner,et al.  Endocrinology: Prediction of ovarian hyperstimulation syndrome of baseline ovarian volume prior to stimulation , 1996 .

[33]  S. Stone,et al.  CLINICAL REPORT: The use of intravenous albumin in patients at high risk for severe ovarian hyperstimulation syndrome , 1993 .

[34]  L. Hann,et al.  The diagnosis of ovarian hyperstimulation (OHS): the impact of ultrasound. , 1983, Fertility and sterility.

[35]  J. Gerris,et al.  Avoiding multiple pregnancies in ART: a plea for single embryo transfer. , 2000, Human reproduction.

[36]  C. Friedman,et al.  Severe ovarian hyperstimulation following follicular aspiration. , 1984, American journal of obstetrics and gynecology.

[37]  E. Rudak,et al.  The treatment of patients with polycystic ovarian syndrome by in-vitro fertilization and embryo transfer: a comparison of results with those of patients with tubal infertility. , 1990, Human reproduction.

[38]  G. Serour,et al.  Reduction of Human Menopausal Gonadotropin Dose Before Coasting Prevents Severe Ovarian Hyperstimulation Syndrome with Minimal Cycle Cancellation , 2000, Journal of Assisted Reproduction and Genetics.

[39]  D. Braat,et al.  Cumulative conception and live birth rates after the treatment of anovulatory infertility: safety and efficacy of ovulation induction in 200 patients. , 1994, Human reproduction.

[40]  L P Hunt,et al.  Distinction between early and late ovarian hyperstimulation syndrome. , 2000, Fertility and sterility.

[41]  N. Amso.  Potential health hazards of assisted reproduction continued: Problems facing the clinician , 1995 .

[42]  L. Veeck,et al.  Cryopreservation of all prezygotes in patients at risk of severe hyperstimulation does not eliminate the syndrome, but the chances of pregnancy are excellent with subsequent frozen-thaw transfers. , 1997, Human reproduction.

[43]  Metabolic characteristics of women who developed ovarian hyperstimulation syndrome. , 2002, Human reproduction.

[44]  A. Brzezinski,et al.  Risk factors and prognostic variables in the ovarian hyperstimulation syndrome. , 1988, American journal of obstetrics and gynecology.

[45]  A. Yuzpe,et al.  Withholding gonadotropins ("coasting") to minimize the risk of ovarian hyperstimulation during superovulation and in vitro fertilization-embryo transfer cycles. , 1999, Fertility and sterility.

[46]  E. Shalev,et al.  Can we abandon routine evaluation of serum estradiol levels during controlled ovarian hyperstimulation for assisted reproduction? , 2001, Fertility and sterility.

[47]  J. Smitz,et al.  Ovarian hyperstimulation syndrome after superovulation using GnRH agonists for IVF and related procedures. , 1992, Human reproduction.

[48]  N. Amso.  Potential health hazards of assisted reproduction. Problems facing the clinician. , 1995, Human reproduction.

[49]  M. Seibel.  Infertility : a comprehensive text , 1989 .

[50]  T. Mukherjee,et al.  Severe ovarian hyperstimulation despite prophylactic albumin at the time of oocyte retrieval for in vitro fertilization and embryo transfer. , 1995, Fertility and sterility.

[51]  J. Itskovitz‐Eldor,et al.  Endocrine profiles after triggering of final oocyte maturation with GnRH agonist after cotreatment with the GnRH antagonist ganirelix during ovarian hyperstimulation for in vitro fertilization. , 2002, The Journal of clinical endocrinology and metabolism.

[52]  M. Sharf,et al.  Ultrasonographic and clinical correlates of menotropin versus sequential clomiphene citrate: menotropin therapy for induction of ovulation. , 1985, Fertility and sterility.

[53]  R. Casper,et al.  Adhesion formation after laparoscopic ovarian cautery for polycystic ovarian syndrome: lack of correlation with pregnancy rate. , 1993, Fertility and sterility.

[54]  M. Hussein,et al.  Limited ovarian stimulation (LOS), prevents the recurrence of severe forms of ovarian hyperstimulation syndrome in polycystic ovarian disease. , 2001, European journal of obstetrics, gynecology, and reproductive biology.

[55]  J. Schenker,et al.  Complications of assisted reproductive techniques. , 1994, Fertility and sterility.

[56]  C. Manna,et al.  Use of Intramuscular Progesterone versus Intravenous Albumin for the Prevention of Ovarian Hyperstimulation Syndrome , 2000, Gynecologic and Obstetric Investigation.

[57]  Tarun Jain,et al.  Insurance coverage and outcomes of in vitro fertilization. , 2002, The New England journal of medicine.

[58]  J. Halme,et al.  A case of severe ovarian hyperstimulation in a healthy oocyte donor. , 1995, Fertility and sterility.

[59]  S. Rozenberg,et al.  A qualitative systematic review of coasting, a procedure to avoid ovarian hyperstimulation syndrome in IVF patients. , 2002, Human reproduction update.

[60]  N. Gleicher,et al.  Octreotide is not useful for clomiphene citrate resistance in patients with polycystic ovary syndrome but may reduce the likelihood of ovarian hyperstimulation syndrome. , 1999, Fertility and sterility.

[61]  L. Gianaroli,et al.  Dopamine treatment for severe ovarian hyperstimulation syndrome. , 1992, Human reproduction.

[62]  M. J. Berger,et al.  Estrogen monitoring and the prevention of ovarian overstimulation during gonadotropin therapy. , 1973, American journal of obstetrics and gynecology.

[63]  K. Vicdan,et al.  Combined approach as an effective method in the prevention of severe ovarian hyperstimulation syndrome. , 2001, European journal of obstetrics, gynecology, and reproductive biology.

[64]  R. Kistner.  Induction of ovulation with clomiphene citrate (clomid). , 1965, Obstetrical & gynecological survey.

[65]  N. Vlahos,et al.  The ovarian hyperstimulation syndrome. , 2000, Fertility and sterility.

[66]  R. Casper,et al.  Effect of follicular aspiration on hormonal parameters in patients undergoing ovarian stimulation. , 1991, Human reproduction.

[67]  L. Nylund,et al.  Androstenedione as a predictor of ovarian hyperstimulation syndrome. , 1992, Human Reproduction.

[68]  J. Emperaire,et al.  Triggering ovulation with endogenous luteinizing hormone may prevent the ovarian hyperstimulation syndrome. , 1991, Human reproduction.

[69]  W. Kuczyński,et al.  Use of GnRH analog for induction of the ovulatory surge of gonadotropins in patients at risk of the ovarian hyperstimulation syndrome. , 1995, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[70]  J. Vandromme,et al.  Unpredictable cases of complicated ovarian hyperstimulation in IVF. , 1997, International journal of fertility and women's medicine.

[71]  B. Urman,et al.  Management of overstimulated gonadotrophin cycles with a controlled drift period. , 1992, Human reproduction.

[72]  G. Serour,et al.  Complications of medically assisted conception in 3,500 cycles. , 1998, Fertility and sterility.

[73]  J. Grudzinskas,et al.  Early unilateral follicular aspiration compared with coasting for the prevention of severe ovarian hyperstimulation syndrome: a prospective randomized study. , 1999, Human reproduction.

[74]  R. Casper,et al.  Use of gonadotropin-releasing hormone agonist to trigger follicular maturation for in vitro fertilization. , 1990, The Journal of clinical endocrinology and metabolism.

[75]  L. Wildt,et al.  von Willebrand factor: an endothelial marker to monitor in-vitro fertilization patients with ovarian hyperstimulation syndrome. , 1993, Human reproduction.

[76]  A. Leader,et al.  Intravenous albumin does not prevent the development of severe ovarian hyperstimulation syndrome in an in-vitro fertilization programme. , 1995, Human reproduction.

[77]  B. Lieberman,et al.  Assisted conception using buserelin and human menopausal gonadotrophins in women with polycystic ovary syndrome , 1994 .

[78]  G. Serour,et al.  Recombinant follicle-stimulating hormone in the treatment of patients with history of severe ovarian hyperstimulation syndrome. , 1996, Fertility and sterility.

[79]  J. Antoine,et al.  Treatment of hyperstimulation during in-vitro fertilization. , 1990, Human reproduction.

[80]  B. Dunphy,et al.  Outcome of thaw embryo transfer after cryopreservation of all embryos in patients at risk of ovarian hyperstimulation syndrome. , 1994, Fertility and sterility.

[81]  N. Whitworth,et al.  Gonadotropin-releasing hormone agonist (leuprolide acetate) induced ovarian hyperstimulation syndrome in a woman undergoing intermittent hemodialysis. , 1991, Fertility and sterility.

[82]  J. Itskovitz‐Eldor,et al.  Severe OHSS: yes, there is a strategy to prevent it! , 2000, Human Reproduction.

[83]  F. Okonofua,et al.  The effect of the dose of human chorionic gonadotropin and the type of gonadotropin stimulation on oocyte recovery rates in an in vitro fertilization program. , 1987, Fertility and sterility.

[84]  S. L. Tan,et al.  A controlled study comparing patients with and without polycystic ovaries undergoing in-vitro fertilization. , 1993, Human reproduction.

[85]  H. Zeyneloglu,et al.  Intravenous albumin prevents moderate-severe ovarian hyperstimulation in in-vitro fertilization patients: a prospective, randomized and controlled study. , 1996, European journal of obstetrics, gynecology, and reproductive biology.

[86]  B. Tarlatzis,et al.  Delaying human chorionic gonadotropin administration in human menopausal gonadotropin-induced cycles decreases successful in vitro fertilization of human oocytes. , 1984, Fertility and sterility.

[87]  C. Matthews,et al.  Failure of body mass index or body weight to influence markedly the response to ovarian hyperstimulation in normal cycling women. , 1990, Fertility and sterility.

[88]  G. Serour,et al.  Oocyte quality in patients with severe ovarian hyperstimulation syndrome. , 1997, Fertility and sterility.

[89]  R. Shaw,et al.  OVARIAN ELECTROCAUTERY VERSUS HUMAN MENOPAUSAL GONADOTROPHINS AND PURE FOLLICLE STIMULATING HORMONE THERAPY IN THE TREATMENT OF PATIENTS WITH POLYCYSTIC OVARIAN DISEASE , 1990, Clinical endocrinology.

[90]  P. Devroey,et al.  Incidence of severe ovarian hyperstimulation syndrome after GnRH agonist/HMG superovulation for in-vitro fertilization. , 1990, Human reproduction.

[91]  M. Goldenberg,et al.  Rescue of menotrophin cycles prone to develop ovarian hyperstimulation , 1987, British journal of obstetrics and gynaecology.

[92]  J. Schenker,et al.  Severe OHSS: An 'epidemic' of severe OHSS: a price we have to pay? , 1999, Human reproduction.

[93]  C. Flamigni,et al.  Endocrine response determines the clinical outcome of pulsatile gonadotropin-releasing hormone ovulation induction in different ovulatory disorders. , 1991, The Journal of clinical endocrinology and metabolism.

[94]  R. Fanchin,et al.  Triggering of ovulation by a gonadotropin-releasing hormone (GnRH) agonist in patients pretreated with a GnRH antagonist. , 1996, Fertility and sterility.

[95]  A. C. Crooke.  Induction of ovulation with gonadotrophins. , 1970, British medical bulletin.

[96]  S. Rozenberg,et al.  Preventive attitude of physicians to avoid OHSS in IVF patients. , 2001, Human reproduction.

[97]  D. Imoedemhe,et al.  O-185. Preventing OHSS in at-risk patients: evidence from a long-term prospective study , 1999 .

[98]  J. Schenker,et al.  Vascular endothelial growth factor plasma levels correlate to the clinical picture in severe ovarian hyperstimulation syndrome. , 1997, Fertility and sterility.

[99]  J. Grudzinskas,et al.  Unilateral ovarian diathermy prior to successful in vitro fertilisation: a strategy to prevent recurrence of ovarian hyperstimulation syndrome? , 2009, Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology.

[100]  J. Grudzinskas,et al.  Timed unilateral ovarian follicular aspiration prior to administration of human chorionic gonadotrophin for the prevention of severe ovarian hyperstimulation syndrome in in-vitro fertilization: a prospective randomized study. , 1997, Human reproduction.

[101]  C. Turan,et al.  Intravenous albumin versus hydroxyethyl starch for the prevention of ovarian hyperstimulation in an in-vitro fertilization programme: a prospective randomized placebo controlled study. , 2001, European journal of obstetrics, gynecology, and reproductive biology.

[102]  G. Bettendorf,et al.  The Ovarian Hyperstimulation Syndrome , 1987, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[103]  R. Casper.  Ovarian hyperstimulation: effects of GnRH analogues. Does triggering ovulation with gonadotrophin-releasing hormone analogue prevent severe ovarian hyperstimulation syndrome? , 1996, Human reproduction.

[104]  A. Ferrari,et al.  Human albumin enhances expression of vascular endothelial growth factor in cultured human luteinizing granulosa cells: importance in ovarian hyperstimulation syndrome. , 1999, Human reproduction.

[105]  J. Garcia,et al.  Abdominal paracentesis for the ovarian hyperstimulation syndrome with severe pulmonary compromise. , 1990, Fertility and sterility.

[106]  E. Shalev,et al.  Induction of pre-ovulatory gonadotrophin surge with gonadotrophin-releasing hormone agonist compared to pre-ovulatory injection of human chorionic gonadotrophins for ovulation induction in intrauterine insemination treatment cycles. , 1995, Human reproduction.

[107]  J. Schenker,et al.  The pathophysiology of ovarian hyperstimulation syndrome--views and ideas. , 1997, Human reproduction.

[108]  A. Penzias.  Luteal Phase Support , 1995, Fertility and sterility.

[109]  H. C. Coelingh Bennink,et al.  Efficacy and safety of recombinant follicle stimulating hormone (Puregon) in infertile women pituitary-suppressed with triptorelin undergoing in-vitro fertilization: a prospective, randomized, assessor-blind, multicentre trial. , 1995, Human reproduction.

[110]  D. Serr,et al.  Ovarian hyperstimulation syndrome: prediction by number and size of preovulatory ovarian follicles* , 1987 .

[111]  N. Amso,et al.  The management of predicted ovarian hyperstimulation involving gonadotropin-releasing hormone analog with elective cryopreservation of all pre-embryos. , 1990, Fertility and sterility.

[112]  R. Johnston,et al.  Clinical and Biological Features , 2001 .

[113]  V. Insler,et al.  Intravenous albumin for the prevention of severe ovarian hyperstimulation syndrome in an in vitro fertilization program: a prospective, randomized, placebo-controlled study. , 1994, Fertility and sterility.

[114]  Z. Ben-Rafael,et al.  A severe case of ovarian hyperstimulation syndrome despite the prophylactic administration of intravenous albumin. , 1995, Fertility and sterility.

[115]  D. Seifer,et al.  Early and late presentation of the ovarian hyperstimulation syndrome: two distinct entities with different risk factors. , 1994, Human reproduction.

[116]  J. Buvat,et al.  Purified follicle-stimulating hormone in polycystic ovary syndrome: slow administration is safer and more effective. , 1989, Fertility and sterility.

[117]  D. Healy,et al.  Low intraovarian vascular resistance: a marker for severe ovarian hyperstimulation syndrome. , 1997, Fertility and sterility.

[118]  S. Daya.  Updated meta-analysis of recombinant follicle-stimulating hormone (FSH) versus urinary FSH for ovarian stimulation in assisted reproduction. , 2002, Fertility and sterility.

[119]  Z. Rosenwaks,et al.  Withholding gonadotropin administration is an effective alternative for the prevention of ovarian hyperstimulation syndrome. , 1997, Fertility and sterility.

[120]  D. Finegood,et al.  The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. , 1996, The Journal of clinical endocrinology and metabolism.

[121]  H. Gjönnaess.  Polycystic ovarian syndrome treated by ovarian electrocautery through the laparoscope. , 1984, Fertility and sterility.

[122]  S. Campbell,et al.  The administration of glucocorticoids for the prevention of ovarian hyperstimulation syndrome in in vitro fertilization: A prospective randomized study , 1993 .

[123]  S. Shapiro,et al.  Plasma estradiol is superior to ultrasound and urinary estriol glucuronide as a predictor of ovarian hyperstimulation during induction of ovulation with menotropins. , 1983, Fertility and sterility.

[124]  L. Gianaroli,et al.  Elective cryopreservation of all pronucleate embryos in women at risk of ovarian hyperstimulation syndrome: efficiency and safety. , 1999, Human reproduction.

[125]  S. Kol,et al.  Ovarian hyperstimulation syndrome after using onadotrophin-releasing hormone analogue as a trigger of ovulation: causes and implications , 1996 .

[126]  Z. Shoham,et al.  The luteinizing hormone surge--the final stage in ovulation induction: modern aspects of ovulation triggering. , 1995, Fertility and sterility.

[127]  J. Gerris,et al.  Triggering of ovulation in human menopausal gonadotrophin-stimulated cycles: comparison between intravenously administered gonadotrophin-releasing hormone (100 and 500 μg), GnRH agonist (buserelin, 500 μg) and human chorionic gonadotrophin (10 000 IU) , 1995 .

[128]  S. Lipitz,et al.  CASE REPORT Quintuplet pregnancy and third degree ovarian hyperstimulation despite withholding human chorionic gonadotrophin , 1991 .

[129]  M. Aboulghar,et al.  GnRH antagonist in assisted reproduction: a Cochrane review. , 2002, Human reproduction.

[130]  J. Itskovitz‐Eldor,et al.  Use of Gonadotropin-Releasing Hormone Agonist to Cause Ovulation and Prevent the Ovarian Hyperstimulation Syndrome , 1993, Clinical obstetrics and gynecology.

[131]  R. Norman,et al.  Differential effects of gonadotrophin-releasing hormone agonists administered as desensitizing or flare protocols on hormonal function in the luteal phase of hyperstimulated cycles. , 1991, Human reproduction.

[132]  M. Brännström,et al.  Peripheral blood concentrations of inhibin B are elevated during gonadotrophin stimulation in patients who later develop ovarian OHSS and inhibin A concentrations are elevated after OHSS onset. , 2000, Human reproduction.

[133]  N. Simberg,et al.  The effect of cryopreservation in prevention of ovarian hyperstimulation syndrome , 1995, British journal of obstetrics and gynaecology.

[134]  M. Feinman,et al.  Eliminating the Risk of Life-Endangering Complications Following Overstimulation With Menotropin Fertility Agents: A Report on Women Undergoing In Vitro Fertilization and Embryo Transfer , 1993, Obstetrics and gynecology.

[135]  M. Seibel,et al.  Ovulation induction in polycystic ovary syndrome with urinary follicle-stimulating hormone or human menopausal gonadotropin. , 1985, Fertility and sterility.

[136]  E. Manseau,et al.  Expression of vascular permeability factor/vascular endothelial growth factor by human granulosa and theca lutein cells. Role in corpus luteum development. , 1995, American Journal of Pathology.

[137]  N. Amso,et al.  Prevention of ovarian hyperstimulation syndrome. , 1991 .

[138]  N. Laufer,et al.  Ovarian hyperstimulation syndrome in novel reproductive technologies: Prevention and treatment , 1993 .

[139]  Y. S. Yang,et al.  Intravenous albumin does not prevent the development of severe ovarian hyperstimulation syndrome. , 1997, Fertility and sterility.

[140]  J. Bódis,et al.  LH/FSH ratio as a predictor of ovarian hyperstimulation syndrome. , 1997, Human reproduction.

[141]  R. Paulson,et al.  Endocrinology: Inhibition of ovarian-derived prorenin to angiotensin cascade in the treatment of ovarian hyperstimulation syndrome , 1995 .

[142]  M. Sütterlin,et al.  Prophylactic intravenous hydroxyethyle starch solution prevents moderate-severe ovarian hyperstimulation in in-vitro fertilization patients: a prospective, randomized, double-blind and placebo-controlled study. , 1998, Human reproduction.

[143]  B. Lieberman,et al.  Outcome of treatment subsequent to the elective cryopreservation of all embryos from women at risk of the ovarian hyperstimulation syndrome. , 1992, Human reproduction.

[144]  J. Maltau,et al.  [In vitro fertilization]. , 1988, Tidsskrift for Den Norske Laegeforening.

[145]  R. Storeng,et al.  The impact of obesity and insulin resistance on the outcome of IVF or ICSI in women with polycystic ovarian syndrome. , 2001, Human reproduction.

[146]  N. Panay,et al.  O-189. Does the prophylactic use of intravenous albumin prevent ovarian hyperstimulation syndrome? A randomized prospective study , 1999 .

[147]  E. Shalev,et al.  The significance of coasting duration during ovarian stimulation for conception in assisted fertilization cycles. , 2002, Human reproduction.

[148]  M. Diamond,et al.  Ovulation induction with human menopausal gonadotropins. , 1986, Obstetrical & gynecological survey.

[149]  J. Balasch,et al.  Triggering of ovulation by a gonadotropin releasing hormone agonist in gonadotropin-stimulated cycles for prevention of ovarian hyperstimulation syndrome and multiple pregnancy. , 1994, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[150]  S. Franks,et al.  Low-dose gonadotrophin therapy for induction of ovulation in 100 women with polycystic ovary syndrome. , 1991, Human reproduction.

[151]  R. Frydman,et al.  Severe ovarian hyperstimulation syndrome using agonists of gonadotropin‐releasing hormone for in vitro fertilization: A European series and a proposal for prevention , 1991, Fertility and sterility.

[152]  P. Devroey,et al.  Comparison of different doses of gonadotropin-releasing hormone antagonist Cetrorelix during controlled ovarian hyperstimulation. , 1997, Fertility and sterility.

[153]  S. Stone,et al.  Severe ovarian hyperstimulation syndrome in assisted reproductive technology: definition of high risk groups. , 1991, Human reproduction.

[154]  L. Hunt,et al.  Does elective cryopreservation of all embryos from women at risk of ovarian hyperstimulation syndrome reduce the incidence of the condition? , 1993, British journal of obstetrics and gynaecology.

[155]  J. Check,et al.  Severe ovarian hyperstimulation syndrome from treatment with urinary follicle-stimulating hormone: two cases. , 1985, Fertility and sterility.

[156]  R. Fanchin,et al.  The use of GnRH antagonists in ovarian stimulation. , 2002, Human reproduction update.

[157]  M. Brännström,et al.  Prospective study of the clinical and laboratory parameters of patients in whom ovarian hyperstimulation syndrome developed during controlled ovarian hyperstimulation for in vitro fertilization. , 1999, Fertility and sterility.

[158]  D. Imoedemhe,et al.  A new approach to the management of patients at risk of ovarian hyperstimulation in an in-vitro fertilization programme. , 1991, Human reproduction.

[159]  A. Yajima,et al.  Laser vaporization of the ovarian surface in polycystic ovary disease results in reduced ovarian hyperstimulation and improved pregnancy rates. , 1995, American journal of obstetrics and gynecology.

[160]  R. Shaw,et al.  The use of laparoscopic ovarian electrocautery in preventing cancellation of in-vitro fertilization treatment cycles due to risk of ovarian hyperstimulation syndrome in women with polycystic ovaries. , 1997, Human reproduction.

[161]  S. Fishel,et al.  Severe ovarian hyperstimulation syndrome: is it really preventable by prophylactic intravenous albumin? , 1997, Fertility and sterility.

[162]  B. Synek,et al.  A Fatal Case Of Ovarian Hyperstimulation Syndrome With Cerebral Infarction , 1995, Pathology.

[163]  A. Lanzone,et al.  The impact of insulin secretion on the ovarian response to exogenous gonadotropins in polycystic ovary syndrome. , 1997, The Journal of clinical endocrinology and metabolism.

[164]  D. Nass,et al.  Ovarian hyperstimulation without elevated serum estradiol associated with pure follicle-stimulating hormone-secreting pituitary adenoma. , 2001, The Journal of clinical endocrinology and metabolism.

[165]  P. De Sutter,et al.  The ovarian hyperstimulation syndrome in in-vitro fertilization: a Belgian multicentric study. II. Multiple discriminant analysis for risk prediction. , 1993, Human reproduction.

[166]  J. Schenker,et al.  Ovarian Hyperstimulation Syndrome: A Current Survey , 1978 .

[167]  J. Gerris,et al.  Endocrinology: Triggering of ovulation using a gonadotrophin-releasing hormone agonist does not prevent ovarian hyperstimulation syndrome , 1993 .

[168]  A. Golan,et al.  Results of in vitro fertilization and embryo transfer by combined long-acting gonadotropin-releasing hormone analog D-Trp-6-luteinizing hormone-releasing hormone and gonadotropins. , 1989, Fertility and sterility.

[169]  E. Adashi,et al.  Surgically induced ovulation in the polycystic ovary syndrome: wedge resection revisited in the age of laparoscopy. , 1995, Fertility and sterility.

[170]  S. L. Tan,et al.  In-vitro fertilization and the ovarian hyperstimulation syndrome. , 1992, Human reproduction.

[171]  R. Rawlins,et al.  Luteal phase support and severe ovarian hyperstimulation syndrome. , 1992, Human reproduction.

[172]  J. Schenker,et al.  Gonadotrophin-releasing hormone agonist and ovarian hyperstimulation syndrome in assisted reproduction. , 1993, Human reproduction.

[173]  M. Nueckel,et al.  Reduced incidence of ovarian hyperstimulation syndrome by prophylactic infusion of hydroxyaethyl starch solution in an in-vitro fertilization programme. , 1997, Human reproduction.

[174]  R. Buyalos,et al.  Polycystic ovary syndrome: pathophysiology and outcome with in vitro fertilization. , 1996, Fertility and sterility.

[175]  D. W. Polson,et al.  Multifollicular Ovaries: Clinical and Endocrine Features and Response to Pulsatile Gonadotropin-Releasing Hormone , 1987 .